Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-DOTA-SNA040
- Development stage
- Phase 1
- Lead developer
- SmartNuclide
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
177Lu-DOTA-SNA040 is a targeted radiopharmaceutical therapeutic candidate developed by Suzhou SmartNuclide Biopharmaceutical. It consists of a ligand (likely a single-domain antibody or nanobody) that specifically binds to **Claudin 18.2 (CLDN18.2)**, conjugated to the beta-emitting radioisotope **Lutetium-177 (177Lu)** via a DOTA chelator. Claudin 18.2 is a tight junction protein that is highly overexpressed in several gastrointestinal cancers, including gastric, pancreatic, and esophageal tumors, while remaining largely absent in healthy tissues. Upon binding to the target cells, the drug delivers localized ionizing radiation, leading to DNA damage and cell death in the tumor mass. It is currently being investigated in first-in-human Phase 1 clinical trials for patients with advanced CLDN18.2-positive solid tumors who have failed standard therapies.
- Other names
- 177Lu-SNA040[177Lu]Lu-DOTA-SNA040
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on 177Lu-DOTA-SNA040.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-DOTA-SNA040.